CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has secured $6.5M in seed funding led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures.
Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.
CyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Or\u00e9al organised in collaboration with Genopole and Hello Tomorrow.
Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.
Agricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.
Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.
Former BioEscalator tenant Alchemab Therapeutics continues to make significant strides in Parkinson's disease research, recently receiving a substantial grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its innovative antibody discovery program.
The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.
With Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.
Nucleome Therapeutics has outgrown its space at the BioEscalator and moved to pastures new. The company will continue its growth journey at The Oxford Science Park.
PepGen is the last of the original cohort of companies that moved into the BioEscalator when it first opened. The new PepGen headquarters in Boston, USA, will manage late-stage preclinical testing and clinical and regulatory functions.
Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.
The shares are expected to begin trading on the Nasdaq Global Select Market on 6 May 2022 under the symbol \u201cPEPG.\u201d The offering is expected to close on 10 May 2022, subject to the satisfaction of customary closing conditions.
The company plans to develop Lilly\u2019s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
Initiation of Phase 1 Study marks PepGen\u2019s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.
The research collaboration will investigate TPOXX\u00ae (tecovirimat) in combination with Bioarchitech\u2019s proprietary vaccinia-based immunotherapy platform in preclinical studies.
Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
![\"\"](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cardiatec-secures-6-5m-seed-funding-to-advance-its-multi-omics-drug-discovery-platform-for-cardiovascular-diseases/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n